Publication de 4 numéros par an
ISSN Imprimer: 0731-8898
ISSN En ligne: 2162-6537
Indexed in
Potentiation of the Photodynamic Action of Hypericin
RÉSUMÉ
Hypericin (HY) is an interesting photosensitizer with dark activity and photodynamic therapy (PDT) effects via p53-independent pathway. In photodynamic diagnosis (PDD) of bladder cancer using HY, very high sensitivity and specificity were reported, in comparison with its counterpart, 5-aminolevulinic acid (5-ALA). HY was tested for the detection of human gastric cancer. It was also studied for treating some cancers and age-related macular degeneration and showed some promising findings. Several strategies to enhance the efficacy of HY-PDD and HY-PDT are reviewed. Using fractionated light dosing, fractionated drug dosing, hyperthermia, adjuvants such as oxygen carrier/antiangiogenesis, chemical modifications, and formulation approaches to enhance the PDT effects of HY are topics of this review. Despite cutting-edge technology approach such as preparing transferring-mediated targeting HY liposomes and nanoparticles of HY, such preparations did not always offer the desired enhanced treatment effects. It turns out that simple solutions of HY, especially those prepared without using plasma protein, were more successful in enhancing the delivery of HY for in vitro and in vivo systems. Thus, the HY-PDT with these formulations performed better. It is anticipated that HY-PDD and HY-PDT can be enhanced and optimized with the right combination of light dosimetry and drug dose in an effective formulation containing a suitable adjuvant. Hyperoxygenation and hyperthermia can also be used to further enhance the efficacy of HY-PDT.
-
Yarnell Eric, Abascal Kathy, Potential of Herbs as Clinical Photosensitizers, Alternative and Complementary Therapies, 18, 4, 2012. Crossref
-
Gándara L., Sandes E., Di Venosa G., Prack Mc Cormick B., Rodriguez L., Mamone L., Batlle A., Eiján A.M., Casas A., The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells, Journal of Photochemistry and Photobiology B: Biology, 133, 2014. Crossref
-
Li Tinghui, Deng Hong, Zhao Jingquan, Gu Ying, Elsinochrome A photosensitizers: Alternative drugs for photodynamic therapy, Journal of Innovative Optical Health Sciences, 08, 01, 2015. Crossref
-
Larisch Patrick, Verwanger Thomas, Linecker Marina, Krammer Barbara, The interrelation between a pro-inflammatory milieu and fluorescence diagnosis or photodynamic therapy of human skin cell lines, Photodiagnosis and Photodynamic Therapy, 11, 2, 2014. Crossref
-
Olivo Malini, Fu Chit Yaw, Raghavan Vijaya, Lau Weber Kam On, New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies, Annals of Biomedical Engineering, 40, 2, 2012. Crossref
-
Wang Shengpeng, Chen Meiwan, Zhou Qi Tony, Chan Hak-Kim, NOVEL FORMULATIONS AND DRUG DELIVERY SYSTEMS FOR PHYTOTHERAPIES, in Phytotherapies, 2015. Crossref
-
Sanovic Renata, Verwanger Thomas, Hartl Arnulf, Krammer Barbara, Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma, Photodiagnosis and Photodynamic Therapy, 8, 4, 2011. Crossref
-
Ware William R., P450 CYP1B1 mediated fluorescent tumor markers: A potentially useful approach for photodynamic therapy, diagnosis and establishing surgical margins, Medical Hypotheses, 72, 1, 2009. Crossref
-
Ritz R., Daniels R., Noell S., Feigl G.C., Schmidt V., Bornemann A., Ramina K., Mayer D., Dietz K., Strauss W.S.L., Tatagiba M., Hypericin for visualization of high grade gliomas: First clinical experience, European Journal of Surgical Oncology (EJSO), 38, 4, 2012. Crossref
-
Lüthi Martin, Besic Gyenge Emina, Engstrüm Mathias, Bredell Marius, Grätz Klaus, Walt Heinrich, Gmür Rudolf, Maake Caroline, Hypericin- and mTHPC-mediated photodynamic therapy for the treatment of cariogenic bacteria, Medical Laser Application, 24, 4, 2009. Crossref
-
Debele Tilahun, Peng Sydney, Tsai Hsieh-Chih, Drug Carrier for Photodynamic Cancer Therapy, International Journal of Molecular Sciences, 16, 9, 2015. Crossref
-
Li Xingshu, Zheng Bing-De, Peng Xiao-Hui, Li Song-Zi, Ying Jia-Wen, Zhao Yuanyuan, Huang Jian-Dong, Yoon Juyoung, Phthalocyanines as medicinal photosensitizers: Developments in the last five years, Coordination Chemistry Reviews, 379, 2019. Crossref
-
Saw Constance L. L., Heng Paul W. S., Hypericin, in Encyclopedia of Cancer, 2017. Crossref
-
Poiroux Guillaume, Barre Annick, Rougé Pierre, Benoist Hervé, Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy, Current Cancer Drug Targets, 19, 5, 2019. Crossref
-
Camargo Vinicius G., Zanuto Vitor S., Astrath Nelson G. C., Caetano Wilker, Hioka Noboru, Pereira Paulo C. S., Gonçalves Renato S., Lukasievicz Gustavo V. B., Herculano Leandro S., Malacarne Luis C., From Protohypericin to Hypericin: Photoconversion Analysis Using a Time-Resolved Thermal Lens Technique, Applied Spectroscopy, 73, 8, 2019. Crossref
-
Saw Constance L. L., Heng Paul W. S., Hypericin, in Encyclopedia of Cancer, 2015. Crossref
-
Sztandera Krzysztof, Gorzkiewicz Michał, Klajnert‐Maculewicz Barbara, Nanocarriers in photodynamic therapy—in vitro and in vivo studies, WIREs Nanomedicine and Nanobiotechnology, 12, 3, 2020. Crossref
-
Wang Zhao, Sun Qianqian, Liu Bin, Kuang Ye, Gulzar Arif, He Fei, Gai Shili, Yang Piaoping, Lin Jun, Recent advances in porphyrin-based MOFs for cancer therapy and diagnosis therapy, Coordination Chemistry Reviews, 439, 2021. Crossref
-
Deng Huaxiang, Liang Xinxin, Liu Jinbin, Zheng Xiaohui, Fan Tai-Ping, Cai Yujie, Advances and perspectives on perylenequinone biosynthesis, Frontiers in Microbiology, 13, 2022. Crossref